🇺🇸 Artesunate + Amodiaquine in United States

8 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 8

Most-reported reactions

1. Bronchopulmonary Aspergillosis — 1 report (12.5%)
2. Cardiogenic Shock — 1 report (12.5%)
3. Deafness Permanent — 1 report (12.5%)
4. Drug Ineffective — 1 report (12.5%)
5. Pulmonary Haemorrhage — 1 report (12.5%)
6. Pyrexia — 1 report (12.5%)
7. Seizure — 1 report (12.5%)
8. Sudden Visual Loss — 1 report (12.5%)

Source database →

Frequently asked questions

Is Artesunate + Amodiaquine approved in United States?

Artesunate + Amodiaquine does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Artesunate + Amodiaquine in United States?

Professor Anders Björkman is the originator. The local marketing authorisation holder may differ — check the official source linked above.